You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. An automated system to interpret echocardiography to predict adverse outcomes in patients with right ventricular dysfunction in daily hospital practice

    SBC: MPROBE, INC.            Topic: NHLBI

    Project Summary Right ventricle (RV) dysfunction is a common and complex form of pediatric heart disease. It is also a common contributor to morbidity and mortality for patients with congenital heart diseases (CHD). Due to the complex geometry of the RV and its relative adaptability to changing physiologic conditions, RV dysfunction is poorly understood and difficult to characterize precisely and ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. An Epithermal Neutron Source for Cancer Therapy

    SBC: ADELPHI TECHNOLOGY INC            Topic: N/A

    DESCRIPTION (provided by applicant): We propose to develop a commercial neutron source for the treatment of brain and liver cancer based on boron neutron capture therapy (BNCT). Boron-containing compounds are injected into a patient's bloodstream and accumulate in a malignant tumor. When irradiated with neutrons, the boron atoms preferentially capture neutrons and decay, releasing short-range radi ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  3. An epitope focused nanoparticle vaccine for MRSA and biodefense

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. A New Anti-inflammatory Therapy for Ischemic Stroke

    SBC: CORNOVUS PHARMACEUTICALS INC.            Topic: NHLBI

    PROJECT SUMMARY Current therapy for ischemic stroke is limited and new treatment is needed since the mortality and morbidity of subjects with this condition remain high. Effort aimed at blocking immune cell- mediated inflammation represents a novel approach. The specific background for the proposed project is that we have identified the myeloid P2X4 receptor (P2X4R), which induces inflammation, as ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. A New In Silico Design Platform for Building Custom Controlled Release Systems

    SBC: Qrono, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Controlled release formulations can improve patient adherence and drug safety or even enable new types of basic medical research. The key to realizing these benefits is the ability to design and produce these formulations in a cost-effectiv and timely manner. Thus far, strategies at improving this process have focused on the development of novel materials and p ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. A New Prostate Cancer Treatment to Improve Outcomes and Reduce Side-effects

    SBC: PXALPHA, L.L.C.            Topic: 102

    PROJECT SUMMARY ABSTRACT Among men prostate cancer is the most common non skin cancer and second leading cause of cancer death with over new diagnoses expected in Approximately of men will be diagnosed with prostate cancer in their lifetime Current treatment options for prostate cancer however have sub optimal incidences of side effects that have a significant impact on pa ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. A new treatment for NSAID-associated gastrointestinal damage

    SBC: Anteana Therapeutics Inc            Topic: NIDDK

    DESCRIPTION provided by applicant Non steroidal anti inflammatory drugs NSAIDs are among the most widely consumed pharmaceuticals but their prolonged use causes gastric injury and damage to the small intestine Previous work has shown that anandamide an endogenous endocannabinoid substance produced in the gastrointestinal GI mucosa plays an important role in epithelial homeostasis and re ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. ANIMAL TESTING OF A BLOCKING ANTIBODY OF PCRV

    SBC: INTERMUNE PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This grant will determine the efficacy of a humanized monoclonal antibody in treating a lethal Pseudomonas-induced lung injury. We have shown that the airspace instillation of a strain of Pseudomonas aeruginosa that contains the type Il system predictably causes lung necrosis, sepsis and death (J Clin Invest 1999). We have also shown th ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  9. An innovative WGS platform for discovery, annotation, and interpretation of all forms of human genetic variation.

    SBC: Base2 Genomics LLC            Topic: 172

    PROJECT SUMMARY Modern DNA sequencing technologies have transformed our ability to interrogate human genomes in a single experimentthereby eliminating the inherent blind spots of gene panels and whole exome sequencingFurthermorerecent speed and economy improvements are driving the cost of whole genome sequencingWGSdown to that of WESthereforewe foresee a transition over the next two years to WGS a ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. An integrative multi phenotype pipeline for drug evaluation pharmacogenomics and attribute prediction

    SBC: PHENVOGEN LLC            Topic: 300

    PROJECT SUMMARY The process of drug discovery is costly and many promising compounds fail during clinical trials By then expenses upward of $ million dollars per failed drug may have incurred and these financial risks hamper research efforts and ultimately reduce the availability of treatment options In this research proposal we are using systematic approaches to map the relationships be ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government